As the deadline for the FDA to decide whether to approve it nears, Biogen’s much-debated Alzheimer’s drug aducanumab faces its moment of truth – and as the author of today’s article notes, Biogen “could bask in glory, but it just as easily could lay an egg, sending not only Biogen stock reeling but also several other biotech stocks.” For more on the enormous implications the FDA’s decision will have for Biogen and the broader biotech sector, CLICK HERE.
A Moment Of Truth For Biogen’s Alzheimer’s Drug – And The Biotech Sector
- by RobH
